Track protection status across key markets to assess launch feasibility.
It is formulated by 1 pharmaceutical company such as NOVARTIS. It is marketed under 1 brand name, including ZYKADIA. Available in 1 different strength, such as 150MG, and administered through 2 routes including CAPSULE;ORAL, TABLET;ORAL.
API availability: Loading API feasibility...
Licensing: 1 potential partnersUS Launch window: Loading launch window...
Stay ahead with worldwide patent expiry and latest updates.
FDA approval history for this ingredient
Stay ahead with worldwide patent expiry insights, exclusivity data, and latest updates.
Key expiration dates for US patents covering this ingredient
Stay ahead with worldwide patent expiry insights, market data, and research updates.
Latest drug strengths approved by FDA
Strength | Route of Administration | Companies | Latest Approval Date |
---|
Patents approved by the FDA for the ingredient
|
Patent Number | Publication Date | Legal Status | Patent Expiry Date | |
---|---|---|---|---|---|
{"application_id":"54380","ingredient":"CERITINIB","trade_name":"ZYKADIA","family_id":"b19f29c9d1324a41b709","publication_number":"US7893074B2","cleaned_patent_number":"7893074","drug_product_flag":"Y","drug_substance_flag":"Y","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2026-04-25","publication_date":"2011-02-22","legal_status":"Granted"} | US7893074B2 Molecular Formulation | 22 Feb, 2011 | Granted | 25 Apr, 2026 | |
{"application_id":"54120","ingredient":"CERITINIB","trade_name":"ZYKADIA","family_id":"e27e90f0a8954e1887fd","publication_number":"US8377921B2","cleaned_patent_number":"8377921","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2027-11-20","publication_date":"2013-02-19","legal_status":"Granted"} | US8377921B2 | 19 Feb, 2013 | Granted | 20 Nov, 2027 | |
{"application_id":"54206","ingredient":"CERITINIB","trade_name":"ZYKADIA","family_id":"e27e90f0a8954e1887fd","publication_number":"US8399450B2","cleaned_patent_number":"8399450","drug_product_flag":"Y","drug_substance_flag":"Y","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2027-11-20","publication_date":"2013-03-19","legal_status":"Granted"} | US8399450B2 Molecular Formulation | 19 Mar, 2013 | Granted | 20 Nov, 2027 | |
{"application_id":"54459","ingredient":"CERITINIB","trade_name":"ZYKADIA","family_id":"b19f29c9d1324a41b709","publication_number":"US7964592B2","cleaned_patent_number":"7964592","drug_product_flag":"Y","drug_substance_flag":"Y","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2028-04-29","publication_date":"2011-06-21","legal_status":"Granted"} | US7964592B2 Molecular Formulation | 21 Jun, 2011 | Granted | 29 Apr, 2028 | |
{"application_id":"54204","ingredient":"CERITINIB","trade_name":"ZYKADIA","family_id":"e27e90f0a8954e1887fd","publication_number":"US8039479B2","cleaned_patent_number":"8039479","drug_product_flag":"Y","drug_substance_flag":"Y","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2030-06-29","publication_date":"2011-10-18","legal_status":"Granted"} | US8039479B2 Molecular Formulation | 18 Oct, 2011 | Granted | 29 Jun, 2030 | |
{"application_id":"54468","ingredient":"CERITINIB","trade_name":"ZYKADIA","family_id":"629e468b600643e29cfa","publication_number":"US9309229B2","cleaned_patent_number":"9309229","drug_product_flag":"Y","drug_substance_flag":"Y","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2032-01-18","publication_date":"2016-04-12","legal_status":"Granted"} | US9309229B2 Molecular Formulation | 12 Apr, 2016 | Granted | 18 Jan, 2032 | |
{"application_id":"54220","ingredient":"CERITINIB","trade_name":"ZYKADIA","family_id":"fbba0158828e4842b8ba","publication_number":"US8703787B2","cleaned_patent_number":"8703787","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2032-02-02","publication_date":"2014-04-22","legal_status":"Granted"} | US8703787B2 | 22 Apr, 2014 | Granted | 02 Feb, 2032 |
Latest clinical trials and research studies for this ingredient
NCT ID | Title | Status | Phase | Conditions | Start Date | Completion Date |
---|
Manufacturing Locations
Unlock access to all suppliers of Ceritinib
Note: Patent expirations and exclusivity timelines are dynamic and may shift based on litigation, regulatory extensions, and maintenance filings. Regular monitoring is advised.